Serum hepcidin in haemodialysis patients: Associations with iron status and microinflammation

Journal of International Medical Research

Volumn 39, Issue 5, 2011, Pages 1961-1967

  Xu, Y ^a   Ding, X Q ^a   Zou, J Z ^a   Liu, Z H ^a   Jiang, S H ^a   Chen, Y M ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Anaemia; Haemodialysis; Hepcidin; High Sensitivity C Reactive Protein; Iron; Microinflammation

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; HEPCIDIN; INTERLEUKIN 6; IRON; TRANSFERRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HORMONE BLOOD LEVEL; HUMAN; INFLAMMATORY DISEASE; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON METABOLISM; MAINTENANCE THERAPY; MALE; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

EID: 80155141148     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900542     Document Type: Article

References (25)

1. Eleftheriadis T, Liakopoulos V, Antoniadi G, et al: The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial 2009; 22: 70-77.
2. KDOQI, National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for anaemia in chronic kidney disease. Am J Kidney Dis 2006; 47(5 suppl 3): S11-S145.
3. Lankhorst CE, Wish JB: Anaemia in renal disease: diagnosis and management. Blood Rev 2010; 24: 39-47.
4. Ford BA, Eby CS, Scott MG, et al: Intraindividual variability in serum hepcidin precludes its use as a marker of iron status in haemodialysis patients. Kidney Int 2010; 78: 769-773.
5. Weiss G, Theurl I, Eder S, et al: Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 2009; 39: 883-890.
6. Hasuike Y, Nonoguchi H, Tokuyama M, et al: Serum ferritin predicts prognosis in haemodialysis patients: the Nishinomiya study. Clin Exp Nephrol 2010; 14: 349-355.
7. Ford BA, Coyne DW, Eby CS, et al: Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int 2009; 75: 104-110.
8. Hamada Y, Fukagawa M: Is hepcidin the star player in iron metabolism in chronic kidney disease. Kidney Int 2009; 75: 873-874.
9. Park CH, Valore EU, Waring AJ, et al: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810.
10. Ganz T, Olbina G, Girelli D, et al: Immunoassay for human serum hepcidin. Blood 2008; 112: 4292-4297.
11. Tsirpanlis G: The pattern of inflammation and a potential new clinical meaning and usefulness of C-reactive protein in end-stage renal failure patients. Kidney Blood Press Res 2005; 28: 55-61.
12. Kuragano T, Shimonaka Y, Kida A, et al: Determinants of hepcidin in patients on maintenance haemodialysis: role of inflammation. Am J Nephrol 2010; 31: 534-540.
13. Nicolas G, Viatte L, Bennoun M, et al: Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis 2002; 29: 327-335.
14. Nemeth E, Ganz T: Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006; 26: 323-342.
15. Cui YJ, Wu QY, Zhou YQ: Iron-refractory iron deficiency anemia:new molecular mechanisms. Kidney Int 2009; 76: 1137-1141.
16. Babitt JL, Lin HY: Molecular mechanisms of hepcidin regulation: implications for the anaemia of CKD. Am J Kidney Dis 2010; 55: 726-741.
17. Nicolas G, Chauvet C, Viatte L, et al: The gene encoding the iron regulatory peptide hepcidin is regulated by anaemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-1044.
18. Zaritsky J, Young B, Gales B, et al: Reduction of serum hepcidin by haemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 2010; 5: 1010-1014.
19. Zaritsky J, Young B, Wang HJ, et al: Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1051-1056.
20. Tessitore N, Girelli D, Campostrini N, et al: Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 2010; 25: 3996-4002.
21. Wrighting DM, Andrews NC: Interleukin-6 induces hepcidin expression through STAT3. Blood 2006; 108: 3204-3209.
22. Rivera S, Nemeth E, Gabayan V, et al: Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 2005; 106: 2196-2199.
23. Sasu BJ, Li H, Rose MJ, et al: Serum hepcidin but not prohepcidin may be an effective marker for anaemia of inflammation (AI). Blood Cells Mol Dis 2010; 45: 238-245.
24. Ashby DR, Gale DP, Busbridge M, et al: Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009; 75: 976-981.
25. Swinkels DW, Wetzels JFM: Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrol Dial Transplant 2008; 23: 2450-2453.